Company intelligence / Profile preview

Humanwell Healthcare Group Co., Ltd.

Wuhan, Hubei Province, Chinaen.humanwell.com.cn ↗

Ownership: Private
Employees: ~17650
Development stage: Commercial

Overview

Humanwell Healthcare has over 250 marketed drugs and more than twenty pipeline programs in clinical development across anesthesia/pain management and other therapeutic areas. The company has achieved US FDA certification for several manufacturing sites and products. Recent clinical progress includes the development of PROTAC compounds targeting IRAK4 as of February 2025.

Therapeutic areas: PulmonologyOtherDermatologyGastroenterologyNeurologyWomen's Health
Modalities: Small moleculesInjectablesOral solid/liquid formulationsSoft capsulesTransdermal genericsHerbal medicines
Industry: Biotech

Drug pipeline

19 assets

HWH486

18 more assets in the full pipeline.

Request access →

Partnerships

AGIC-HUMANWELL BLUE RIDGE

Beyond the preview

Go deeper on Humanwell Healthcare Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Humanwell Healthcare Group Co., Ltd..

Explore the full profile